Elizabeth RuggieroResearch Assistant II HSSDownloadHi-Res PhotoCardsContact Infoelizabeth.ruggiero@yale.eduLearn moreabout Contact InfoAboutResearchLinksGet In TouchAboutCopy LinkTitlesResearch Assistant II HSSDepartments & OrganizationsInternal MedicineMetabolic Health & Weight Loss ProgramResearchCopy LinkResearch at a GlanceYale Co-AuthorsFrequent collaborators of Elizabeth Ruggiero's published research.Badr Al Bawardy, MDView Full ProfileView Common PublicationDeborah Proctor, MDView Full ProfileView Common PublicationKenneth Hung, MD, MSView Full ProfileView Common PublicationPublications2020The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter StudyRamos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedArthritisFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritisNewsCopy LinkNewsApril 27, 2026Yale Department of Internal Medicine Celebrates Staff Service AnniversariesRead moreabout Yale Department of Internal Medicine Celebrates Staff Service AnniversariesGet In TouchCopy LinkContactsEmailelizabeth.ruggiero@yale.edu
The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter StudyRamos GP, Dimopoulos C, McDonald NM, Janssens LP, Hung KW, Proctor D, Ruggiero E, Kane S, Bruining DH, Faubion WA, Raffals LE, Loftus EV, Al-Bawardy B. The Impact of Vedolizumab on Pre-Existing Extraintestinal Manifestations of Inflammatory Bowel Disease: A Multicenter Study. Inflammatory Bowel Diseases 2020, 27: 1270-1276. PMID: 33165569, DOI: 10.1093/ibd/izaa293.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedArthritisFemaleHumansInflammatory Bowel DiseasesMaleMiddle AgedRetrospective StudiesConceptsInflammatory bowel diseaseExtraintestinal manifestationsPeripheral arthritisBowel diseaseDose of vedolizumabPrevious biologic useMulticenter retrospective studyCurrent medical therapyTerms of ageConcurrent immunosuppressantsCorticosteroid therapyVDZ treatmentIBD subtypesBiologic useSecondary outcomesMedical therapyPrimary outcomeClinical outcomesMulticenter studyRetrospective studyVedolizumabPatientsCommon typeDiscontinuationArthritis
April 27, 2026Yale Department of Internal Medicine Celebrates Staff Service AnniversariesRead moreabout Yale Department of Internal Medicine Celebrates Staff Service Anniversaries